15 active not recruiting, 14 completed, 13 terminated, 6 recruiting. 53 Phase 1, 20 Phase 2.
Follow Imfinzi: new trials by email Literature Review of Imfinzi trials Research Report on Imfinzi
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer Biopsy Procedure, Cisplatin, Computed Tomography - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 46 | 2026-05-29 | 2026-08-20 |
| Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer Emavusertib, Gemcitabine, Cisplatin - Metastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma | Phase 1 | Recruiting | Washington University School of Medicine | 48 | 2026-03-27 | 2026-04-03 |
| Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 45 | 2025-04-08 | 2026-10-29 |
| Trial of INI-4001 in Patients With Advanced Solid Tumours INI-4001, Nivolumab, Pembrolizumab - Advanced Solid Tumor | Phase 1 | Completed | Inimmune Corporation | 10 | 2024-07-01 | 2026-10-16 |
| Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma Angiography, Biopsy, Biospecimen Collection - Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma | Phase 1 | Recruiting | Mayo Clinic | 16 | 2024-06-06 | 2026-05-13 |
| Tumor Treating Fields for Locally Advanced NSCLC carboplatin chemotherapy, NovoTTF-200T (TTFields) System, Durvalumab - Non Small Cell Lung Cancer | Phase 1 | Withdrawn | University of Utah | 2024-04-04 | 2026-08-03 | |
| Abequolixron (RGX-104) and Durvalumab in Lung Cancer Durvalumab, Carboplatin, Abequolixron - Non-Small Cell Lung Cancer | Phase 1 | Terminated | UNC Lineberger Comprehensive Cancer Center | 1 | 2024-04-01 | 2025-03-21 |
| Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy Imfinzi, Opdivo - Locally Advanced Rectal Carcinoma | Phase 1 | Unknown | University Medical Center Groningen | 18 | 2024-04-01 | 2024-03-12 |
| Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer Surufatinib, Durvalumab - Biliary Tract Cancer | Phase 1 / Phase 2 | Unknown | China Medical University, China | 30 | 2024-02-15 | 2024-02-13 |
| DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) Durvalumab, DRP-104 - Fibrolamellar Hepatocellular Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 6 | 2024-02-12 | 2026-10-22 |
| Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy Durvalumab, Rintatolimod - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Active not recruiting | Joachim Aerts, MD PhD | 43 | 2024-01-09 | 2026-09-29 |
| Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen Durvalumab, Radiation Therapy, Biospecimen Collection - Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 | Phase 1 | Terminated | Mayo Clinic | 4 | 2024-01-08 | 2026-02-06 |
| Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 18 | 2023-05-22 | 2026-07-10 |
| SIRT With Tremelimumab and Durvalumab for Resectable HCC Durvalumab, Tremelimumab, SIRT - Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma | Phase 1 | Active not recruiting | Jiping Wang, MD, PhD | 20 | 2023-04-21 | 2026-08-13 |
| Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases Olaparib, Stereotactic Radiosurgery, Durvalumab - Breast Cancer, Brain Metastases, Adult | Phase 1 / Phase 2 | Active not recruiting | Colette Shen | 41 | 2022-03-09 | 2026-07-10 |
| Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma Belinostat, Durvalumab - Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma | Phase 1 | Completed | University of Utah | 7 | 2022-01-14 | 2026-10-14 |
| Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer Carboplatin, Durvalumab, Paclitaxel - Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 28 | 2021-12-06 | 2026-06-30 |
| Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer Durvalumab, Tremelimumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 25 | 2021-08-03 | 2026-04-20 |
| Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab consolidative hypofractionated radiation therapy (hfRT), Durvalumab 50 MG/ML - Lung Cancer, Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Terminated | University of Nebraska | 6 | 2021-07-15 | 2026-06-05 |
| Lung Cancer With Copanlisib and Durvalumab Durvalumab, Copanlisib - Non Small Cell Lung Cancer | Phase 1 | Completed | Zhonglin Hao | 11 | 2021-05-12 | 2025-11-18 |
Showing 20 of 53. Sign in to see all of them.
Lung Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (9) · Pancreatic Neoplasms (5) · Carcinoma, Hepatocellular (4) · Squamous Cell Carcinoma of Head and Neck (4) · Urinary Bladder Neoplasms (4) · Breast Neoplasms (3) · Carcinoma, Transitional Cell (3) · Cholangiocarcinoma (3) · Biliary Tract Neoplasms (2) · Colorectal Neoplasms (2) · Fallopian Tube Neoplasms (2) · Lymphoma, Non-Hodgkin (2) · Neoplasm Metastasis (2) · Triple Negative Breast Neoplasms (2)
M.D. Anderson Cancer Center (8) · National Cancer Institute (NCI) (5) · Mayo Clinic (3) · Washington University School of Medicine (3) · H. Lee Moffitt Cancer Center and Research Institute (2) · Jonsson Comprehensive Cancer Center (2) · OHSU Knight Cancer Institute (2) · University of Utah (2) · AVEO Pharmaceuticals, Inc. (1) · AstraZeneca (1) · China Medical University, China (1) · City of Hope Medical Center (1) · Colette Shen (1) · Daniel George, MD (1) · Emory University (1)
United States (44) · Netherlands (3) · China (2) · Australia (1) · Belgium (1) · Canada (1) · Germany (1) · Italy (1) · Japan (1) · Poland (1) · South Korea (1) · Spain (1) · Taiwan (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Alberto A Chiappori, MD (1) · Amir A Jazaeri (1) · Apar Ganti, MD, MS (1) · Casper van Eijck, Prof, MD, PhD (1) · Chandrikha Chandrasekharan, MD (1) · Charles M Rudin (1) · Christine Chung, M.D. (1) · Colette Shen, M.D., Ph.D (1) · Cristina P. Rodriguez (1) · Daneng Li (1) · Dawn Owen, MD (1) · Don L Gibbons (1) · Gino K In, MD (1) · Jared Weiss, MD (1) · Jennifer W Carlisle, MD (1)
PMID 32269052, PMID 32379297, PMID 34515338, PMID 36912078, PMID 37903325, PMID 38410608, PMID 38820888, PMID 39551600, PMID 39863139, PMID 40580957, PMID 42310313
P30CA015704 (2), 2023 (1), P30CA014089 (1), P30CA033572 (1), P30CA046592 (1), P30CA138292 (1), P50CA217691 (1), R01CA136551 (1), R01CA240983 (1), R01CA262388 (1), R01CA274985 (1), R01CA294704 (1), U10CA180868 (1), UM1CA186688 (1), UM1CA186691 (1)